journal
MENU ▼
Read by QxMD icon Read
search

Journal of Prevention of Alzheimer's Disease

journal
https://www.readbyqxmd.com/read/29972215/an-action-plan-to-face-the-challenge-of-dementia-international-statement-on-dementia-from-iap-for-health
#1
H Chertkow
An international committee set up through the IAP for Health met to develop an action plan for dementia. Comprehensive international and national initiatives should move forward with calls for action that include increased public awareness regarding brain health and dementia, support for a broad range of dementia research objectives, and investment in national health care systems to ensure timely competent person-centred care for individuals with dementia. The elements of such action plans should include: 1) Development of national plans including assessment of relevant lifecourse risk and protective factors; 2) Increased investments in national research programs on dementia with approximately 1% of the national annual cost of the disease invested; 3) Allocating funds to support a broad range of biomedical, clinical, and health service and systems research; 4) Institution of risk reduction strategies; 5) Building the required trained workforce (health care workers, teachers, and others) to deal with the dementia crisis; 6) Ensuring that it is possible to live well with dementia; and 7) Ensuring that all have access to prevention programs, care, and supportive living environments...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972214/correlation-of-csf-and-mri-biomarkers-and-progression-of-cognitive-decline-in-an-open-label-mci-trial
#2
L K Joachim, L Frölich, E Rüther, J Wiltfang, W Maier, J Kornhuber, C Bauer, I Heuser, O Peters
In several randomized controlled trials (RCT) acetylcholinesterase-inhibitors (AChE-I) were tested in patients with mild cognitive impairment (MCI) but were ineffective in delaying disease progression as determined by neuropsychological testing only. Here we present data from an open label observational extension of a multicenter RCT in order to assess if biomarkers are providing useful additional information about a drug's efficacy. We followed 83 amnestic MCI patients and performed correlational analyses of Aβ 1-42 and total-Tau in the cerebrospinal fluid (CSF), hippocampal and amygdala volume at baseline, the total duration of blinded and open label AChE-I treatment and the outcome 24 months after inclusion into the RCT...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972213/auraptene-in-the-peels-of-citrus-kawachiensis-kawachibankan-contributes-to-the-preservation-of-cognitive-function-a-randomized-placebo-controlled-double-blind-study-in-healthy-volunteers
#3
M Igase, Y Okada, M Ochi, K Igase, H Ochi, S Okuyama, Y Furukawa, Y Ohyagi
OBJECTIVES: Dementia, which is characterized by a progressive decline in cognitive function, is a major concern in aging societies. Although a number of treatments have been approved, an effective therapy to prevent the disorder is lacking. A supplement that improves cognitive function would benefit patients. The aim of this study was to assess whether auraptene, a citrus coumarin, has a protective effect on cognitive decline. DESIGN: A randomized, placebo-controlled, double-blind study SETTING: Outpatient medical check-up program for cognitive disorders PARTICIPANTS: 84 adult volunteers (they are cognitively normal) met inclusion and exclusion criteria to participate...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972212/detection-of-rater-errors-on-cognitive-instruments-in-a-clinical-trial-setting
#4
D J Connor, C W Jenkins, D Carpenter, R Crean, P Perera
OBJECTIVES: This study examines errors committed by raters in a clinical trial of a memory enhancement compound. BACKGROUND: Findings of clinical trials are directly dependent on the quality of the data obtained but there is little literature on rates or nature of rater errors on cognitive instruments in a multi-site setting. DESIGN: Double-blind placebo-controlled study. SETTING: 21 clinical sites in North America. PARTICIPANTS: Two hundred seventy-five participants...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972211/analysis-of-the-relationship-of-cognitive-impairment-and-functional-impairment-in-mild-alzheimer-s-disease-in-expedition-3
#5
H Liu-Seifert, E Siemers, K Sundell, M Mynderse, J Cummings, R Mohs, P Aisen
BACKGROUND: Clinical progression of Alzheimer's disease is characterized by impairment in cognition and function. OBJECTIVE: To assess the relationship between cognitive and functional impairment in mild Alzheimer's disease. DESIGN: Spearman's rank correlations between cognitive and functional measures were calculated. Autoregressive cross-lagged panel analyses were used to determine the temporal relationship between cognitive and functional decline...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972210/effects-of-a-six-month-multi-ingredient-nutrition-supplement-intervention-of-omega-3-polyunsaturated-fatty-acids-vitamin-d-resveratrol-and-whey-protein-on-cognitive-function-in-older-adults-a-randomised-double-blind-controlled-trial
#6
C Moran, A Scotto di Palumbo, J Bramham, A Moran, B Rooney, G De Vito, B Egan
OBJECTIVES: To investigate the impact of a six-month multi-ingredient nutrition supplement intervention (Smartfish®), containing omega-3 polyunsaturated fatty acids (PUFAs), vitamin D, resveratrol, and whey protein, on cognitive function in Irish older adults. DESIGN: Double-blind, randomised controlled trial (ClinicalTrials.gov: NCT02001831). A quantitative, mixed-model design was employed in which the dependent variable (cognitive function) was analysed with a between-subjects factor of group (placebo, intervention) and within-subjects factor of testing occasion (baseline, three-months, six-months)...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972209/what-have-we-learned-from-expedition-iii-and-epoch-trials-perspective-of-the-ctad-task-force
#7
P S Aisen, E Siemers, D Michelson, S Salloway, C Sampaio, M C Carrillo, R Sperling, R Doody, P Scheltens, R Bateman, M Weiner, B Vellas
Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972208/commentary-fatty-acids-and-alzheimer-s-disease-evidence-on-cognition-and-cortical-%C3%AE-amyloid-from-secondary-analyses-of-the-multidomain-alzheimer-preventive-trial
#8
C Hooper, B Vellas
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972207/editorial-who-guidelines-on-community-level-interventions-to-manage-declines-in-intrinsic-capacity-the-road-for-preventing-cognitive-declines-in-older-age
#9
B Vellas, D Scrase, G A Rosenberg, S Andrieu, I Araujo de Carvalho, L T Middleton
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972206/editorial-turning-point-towards-blood-biomarker-guided-targeted-therapy-for-precision-medicine-in-alzheimer-s-disease
#10
H Hampel, A Vergallo, U Bonuccelli, S Lista
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972205/editorial-plasma-biomarker-for-alzheimer-s-disease-are-we-ready-now-for-clinical-practice-and-drug-trials
#11
A Nakamura
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616710/letter-to-editor-nanorobots-the-future-of-neurology-a-perspective-on-alzheimer-s-disease
#12
C Hooper, S Layé
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616709/development-of-azeliragon-an-oral-small-molecule-antagonist-of-the-receptor-for-advanced-glycation-endproducts-for-the-potential-slowing-of-loss-of-cognition-in-mild-alzheimer-s-disease
#13
A H Burstein, M Sabbagh, R Andrews, C Valcarce, I Dunn, L Altstiel
Increasing evidence supports the role of the Receptor for Advanced Glycation Endproducts (RAGE) in the pathology of Alzheimer's disease. Azeliragon (TTP488) is an orally bioavailable small molecule inhibitor of RAGE in Phase 3 development as a potential treatment to slow disease progression in patients mild AD. Preclinical studies in animal models of AD (tgAPPSwedish/London) have shown azeliragon to decrease Aβ plaque deposition; reduce total Aβ brain concentration while increasing plasma Aβ levels; decreases sAPPβ while increasing sAPPα; reduce levels of inflammatory cytokines; and slow cognitive decline and improve cerebral blood flow...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616708/strong-relationship-between-malnutrition-and-cognitive-frailty-in-the-singapore-longitudinal-ageing-studies-slas-1-and-slas-2
#14
L Chye, K Wei, M S Z Nyunt, Q Gao, S L Wee, T P Ng
BACKGROUND: Physical frailty is well known to be strongly associated with malnutrition, but the combined impact of physical frailty and cognitive impairment among non-demented older persons (cognitive frailty) on malnutrition prevalence is not well documented. DESIGN: Cross-sectional cohort study. SETTING AND PARTICIPANTS: Community-dwelling older Singaporeans aged ≥55y (n=5414) without dementia in the Singapore Longitudinal Ageing Study (SLAS-1 and SLAS-2)...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616707/adherence-to-the-mediterranean-diet-is-not-related-to-beta-amyloid-deposition-data-from-the-women-s-healthy-ageing-project
#15
E Hill, C Szoeke, L Dennerstein, S Campbell, P Clifton
BACKGROUND: Research has indicated the neuroprotective potential of the Mediterranean diet. Adherence to the Mediterranean diet has shown preventative potential for Alzheimer's disease incidence and prevalence, yet few studies have investigated the impact of Mediterranean diet adherence on the hallmark protein; beta-amyloid. OBJECTIVES: To investigate the association between Mediterranean diet adherence and beta-amyloid deposition in a cohort of healthy older Australian women...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616706/the-integrated-alzheimer-s-disease-rating-scale-iadrs-findings-from-the-expedition3-trial
#16
A M Wessels, S W Andersen, S A Dowsett, E R Siemers
The Integrated Alzheimer's Disease (AD) Rating Scale (iADRS) is a composite tool that combines scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the AD Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). It demonstrates acceptable psychometric properties, and is effective in capturing both disease progression and separation of placebo and active drug effect. We assessed the performance of iADRS in the solanezumab EXPEDITION3 study, an 80-week, placebo-controlled study of individuals with mild AD dementia...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616705/a-literature-review-of-methodologies-used-in-randomized-clinical-trials-of-agitation-in-alzheimer-s-disease
#17
S Dubé, J T Megerian, R Malamut
Agitation is a common and burdensome symptom associated with Alzheimer's disease (AD). This is a narrative literature review of the designs and methods used in randomized clinical trials of agitation in patients with AD; sources range from published, to completed but not published, to ongoing studies in the past 10 years. Selection for review included blinded, randomized trials conducted to assess the effect of a pharmacological intervention for which agitation in patients with AD was among the prespecified end points...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616704/minimizing-the-sample-sizes-of-clinical-trials-on-preclinical-and-early-symptomatic-stage-of-alzheimer-disease
#18
J Luo, H Weng, J C Morris, C Xiong
BACKGROUND: Clinical trials of investigational drugs for Alzheimer disease (AD) increasingly focus on the prodromal (symptomatic) stage of the illness and now its preclinical (asymptomatic) stage. Sensitive and specific cognitive and functional endpoints are needed to track subtle cognitive and functional changes in the early and preclinical stages to minimize sample sizes in these trials. OBJECTIVES: To identify informative items in a standard clinical assessment protocol and a psychometric battery that are predictive of onset of dementia symptom...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616703/biomarker-and-clinical-trial-design-support-for-disease-modifying-therapies-report-of-a-survey-of-the-eu-us-alzheimer-s-disease-task-force
#19
J Cummings, N Fox, B Vellas, P Aisen, G Shan
BACKGROUND: Disease-modifying therapies are urgently needed for the treatment of Alzheimer's disease (AD). The European Union/United States (EU/US) Task Force represents a broad range of stakeholders including biopharma industry personnel, academicians, and regulatory authorities. OBJECTIVES: The EU/US Task Force represents a community of knowledgeable individuals who can inform views of evidence supporting disease modification and the development of disease-modifying therapies (DMTs)...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29616702/identifying-better-outcome-measures-to-improve-treatment-of-agitation-in-dementia-a-report-from-the-eu-us-ctad-task-force
#20
M Sano, M Soto, M Carrillo, J Cummings, S Hendrix, J Mintzer, A Porsteinsson, P Rosenberg, L Schneider, J Touchon, P Aisen, B Vellas, C Lyketsos
For the second time in the past 3 years, the EU-US CTAD Task Force addressed challenges related to designing clinical trials for agitation in dementia, which is one of the most disruptive aspects of the condition for both patients and caregivers. Six recommendations emerged from the Task Force meeting: 1 - Operationalizing agitation criteria established by the IPA; 2 - Combining clinician- and caregiver-derived outcomes as primary outcome measures; 3 - Using global ratings to define clinically meaningful effects and power studies; 4 - Improving the accuracy of caregiver reports by better training and education of caregivers; 5 - Employing emerging technologies to collect near real-time behavioral data; and 6 - Utilizing innovative trial designs and increasing the use of biomarkers to maximize the productivity of clinical trials for neuropsychiatric symptoms...
2018: Journal of Prevention of Alzheimer's Disease
journal
journal
48972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"